HPGC Renmintongtai Pharmaceutical (600829.SS) Earnings Analysis
HPGC Renmintongtai Pharmaceutical (600829.SS) has no confirmed upcoming earnings date. Trailing P/E 38.42.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does 600829.SS next report earnings?
No confirmed upcoming earnings date is currently scheduled for 600829.SS. This page updates as the calendar is published.
600829.SS earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2025-09-29 | 0.06777 CNY | n/a | n/a | n/a |
| 2025-06-06 | 0.04614 CNY | n/a | n/a | n/a |
| 2025-03-31 | 0.0791 CNY | n/a | n/a | n/a |
600829.SS valuation and analyst view
| Trailing P/E | 38.42 |
|---|---|
| Trailing EPS | 0.2354 CNY |
| Price / book | 1.71 |
| Dividend yield | 0.00% |
| Market cap | 5.21B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is HPGC Renmintongtai Pharmaceutical (600829.SS)'s next earnings date?
No confirmed upcoming earnings date is currently scheduled for 600829.SS. This page updates as the calendar is published.
Did 600829.SS beat earnings last quarter?
Consensus estimate data was not available for 600829.SS's 2025-09-29 report.
What is 600829.SS's current P/E ratio and EPS?
600829.SS trades at a trailing P/E of 38.42 on trailing EPS of 0.23539771490806 CNY.
What do analysts rate 600829.SS?
600829.SS has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.